Wedbush Upgrades Karyopharm Therapeutics (KPTI) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $0.09 -18.18%
Rating Summary:
10 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
10 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Wedbush analyst David Nierengarten upgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Neutral to Outperform with a price target of $19.00.
For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.
Shares of Karyopharm Therapeutics closed at $11.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rodman & Renshaw Downgrades Karyopharm Therapeutics (KPTI) to Neutral
- Ambit Capital Upgrades Hitachi Energy India Ltd (POWERIND:IN) to Buy (1)
- Goldman Sachs Upgrades Ibotta Inc (IBTA) to Neutral
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
